Corporate Presentation May 2022 NASDAQ: OTLK outlooktherapeutics.com | --- | --- | --- | |---------------|------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for bevacizumab in | | | ophthalmology | | 2 | Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutic ...